AUTOCAST

Automatic Cancer Screening Based on Real-time PCR

Coordinatore	"GENOID MOLEKULARBIOLOGIAI KUTATO, GYARTO ES EGESZSEGUGYI SZOLGALATO KFT"    more  Organization address address: ROPPENTYU UTCA 48 city: BUDAPEST postcode: 1139 contact info Titolo: Dr. Nome: Csaba Cognome: Jeney Email: send email Telefono: -554 Fax: -557
Nazionalità Coordinatore	Hungary [HU]
Sito del progetto	http://www.genoid.net/index.php/autocast/introduction/
Totale costo	4˙146˙008 €
EC contributo	2˙999˙769 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-08-01   -   2012-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	"GENOID MOLEKULARBIOLOGIAI KUTATO, GYARTO ES EGESZSEGUGYI SZOLGALATO KFT"  Organization address address: ROPPENTYU UTCA 48 city: BUDAPEST postcode: 1139 contact info Titolo: Dr. Nome: Csaba Cognome: Jeney Email: send email Telefono: -554 Fax: -557	HU (BUDAPEST)	coordinator	0.00
2	AIT Austrian Institute of Technology GmbH  Organization address address: Donau-City-Strasse 1 city: WIEN postcode: 1220 contact info Titolo: Mr. Nome: Alexander Cognome: Svejkovsky Email: send email Telefono: +43 (0) 50550-6322 Fax: +43 (0) 50550-6590	AT (WIEN)	participant	0.00
3	ALBERT-LUDWIGS-UNIVERSITAET FREIBURG  Organization address address: FAHNENBERGPLATZ city: FREIBURG postcode: 79085 contact info Titolo: Dr. Nome: Felix Cognome: Von Stetten Email: send email Telefono: 497612000000 Fax: 497612000000	DE (FREIBURG)	participant	0.00
4	BIOFLUIDIX GMBH  Organization address address: GEORGE KOEHLER ALLEE 103 city: FREIBURG IM BREISGAU postcode: 79110 contact info Titolo: Dr. Nome: Peter Cognome: Koltay Email: send email Telefono: +49 761 203 7282 Fax: +49 761 203 7284	DE (FREIBURG IM BREISGAU)	participant	0.00
5	FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V  Organization address address: Hansastrasse 27C city: MUENCHEN postcode: 80686 contact info Titolo: Mr. Nome: Maximilian Cognome: Steiert Email: send email Telefono: -12052761 Fax: -12057574	DE (MUENCHEN)	participant	0.00
6	JENOPTIK POLYMER SYSTEMS GMBH  Organization address address: AM SANDBERG 2 city: TRIPTIS postcode: 7819 contact info Titolo: Ms. Nome: Janine Cognome: Müller Email: send email Telefono: -36610 Fax: -36700	DE (TRIPTIS)	participant	0.00
7	THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN  Organization address address: College Green - city: DUBLIN postcode: 2 contact info Titolo: Ms. Nome: Deirdre Cognome: Savage Email: send email Telefono: + 353 1 896 1942 Fax: +353 1 707 1633	IE (DUBLIN)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cancer accounts for nearly one-quarter of deaths in the developed world, exceeded only by heart diseases. One of the key strategies in cancer prevention is early diagnosis through cancer screening programs. Estimates of the premature deaths that could have been avoided through cancer screening vary from 3% to 35%, depending on a variety of assumptions. Beyond the potential to reduce mortality, screening may reduce cancer morbidity since treatment for earlier-stage cancers is often less aggressive than that for more advanced-stage cancers. Currently many of these screening programs, have issues with false negative results, long time delays to obtaining the results, which increase patient anxiety and delays in starting treatments. In this project we will develop a novel rapid real time PCR/probe technology, in a microarray biochip format with the corresponding automated instrumentation for use as a rapid “point of care” diagnostic device. Cervical cancer and its associated virus, human papilloma virus is the model system which will be used to develop this novel automated cancer screening technology. The novel real time PCR technology will permit detection of panels of multiple biomarkers in a single PCR reaction. The partners have already developed prototype technology which partly demonstrates a microarray approach to real time PCR. The project will build on this, providing the innovation needed to transform a promising technology to an integrated system suitable for practical use at point-of-care setting. The consortium includes four research institutes and two SMEs, who have extensive experience with real time PCR and microarray technologies, and are motivated to commercialise results. In addition partners 7 will act as end user, validating the system in a clinical setting.'